{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:14:24Z","timestamp":1740140064828,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Personalized Medicine Partnership for Cancer"},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>ALK tyrosine kinase inhibition has become a mainstay in the clinical management of ALK fusion positive NSCLC patients. Although ALK mutations can reliably predict the likelihood of response to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, they cannot reliably predict response duration or intrinsic\/extrinsic therapeutic resistance. To further refine the application of personalized medicine in this indication, this study aimed to identify prognostic proteomic biomarkers in ALK fusion positive NSCLC patients to crizotinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty-four patients with advanced NSCLC harboring ALK fusion were administered crizotinib in a phase IV trial which included blood sampling prior to treatment. Targeted proteomics of 327 proteins using MRM-MS was used to measure plasma levels at baseline (including pre-treatment and early treatment blood samples) and assess potential clinical association.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients were categorized by duration of response: long-term responders [PFS\u2009\u2265\u200924\u00a0months (n\u2009=\u20097)], normal responders [3\u2009&lt;\u2009PFS\u2009&lt;\u200924\u00a0months (n\u2009=\u200910)] and poor responders [PFS\u2009\u2264\u20093\u00a0months (n\u2009=\u20095)]. Several proteins were identified as differentially expressed between long-term responders and poor responders, including DPP4, KIT and LUM. Next, using machine learning algorithms, we evaluated the classification potential of 40 proteins. Finally, by integrating the different analytic methods, we selected 22 proteins as potential candidates for a blood-based prognostic signature of response to crizotinib in NSCLC patients harboring ALK fusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conjunction with ALK mutation, the expression of this proteomic signature may represent a liquid biopsy-based marker of long-term response to crizotinib in NSCLC. Expanding the utility of prognostic biomarkers of response duration could influence choice of therapy, therapeutic sequencing, and potentially the need for alternative or combination therapy.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>ClinicalTrials.gov, NCT02041468. Registered 22 January 2014,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02041468?term=NCT02041468&amp;rank=1\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02041468?term=NCT02041468&amp;rank=1<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1186\/s12014-020-9269-6","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T08:02:49Z","timestamp":1581062569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition"],"prefix":"10.1186","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct02041468","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mathilde","family":"Cou\u00ebtoux du Tertre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzan","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Gambaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrla","family":"Hoffert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razvan","family":"Diaconescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Normand","family":"Blais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Couture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Pelsser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Hindie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Parent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick-Andr\u00e9","family":"Breton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenael","family":"Pottiez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Croteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Higenell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Izzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Spatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Batist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Agulnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"issue":"19","key":"9269_CR1","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998\u20132006.","journal-title":"JAMA"},{"issue":"9","key":"9269_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240\u20132.","journal-title":"J Thorac Oncol"},{"issue":"7511","key":"9269_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543\u201350.","journal-title":"Nature"},{"issue":"7153","key":"9269_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136.","journal-title":"Nature"},{"issue":"2","key":"9269_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.lungcan.2013.03.017","volume":"81","author":"S Peters","year":"2013","unstructured":"Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R. Treatment and detection of ALK-rearranged NSCLC. Lung Cancer. 2013;81(2):145\u201354.","journal-title":"Lung Cancer"},{"issue":"10","key":"9269_CR6","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1158\/1078-0432.CCR-14-2791","volume":"21","author":"R Katayama","year":"2015","unstructured":"Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res. 2015;21(10):2227\u201335.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"9269_CR7","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118\u201333.","journal-title":"Cancer Discov"},{"key":"9269_CR8","first-page":"169","volume":"8","author":"RK Jain","year":"2017","unstructured":"Jain RK, Chen H. Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib. Lung Cancer (Auckl). 2017;8:169\u201377.","journal-title":"Lung Cancer (Auckl)"},{"issue":"2","key":"9269_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","volume":"7","author":"JJ Lin","year":"2017","unstructured":"Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017;7(2):137\u201355.","journal-title":"Cancer Discov"},{"issue":"3","key":"9269_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/17476348.2015.1009040","volume":"9","author":"M Santarpia","year":"2015","unstructured":"Santarpia M, Altavilla G, Rosell R. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. Expert Rev Respir Med. 2015;9(3):255\u201368.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"9269_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","volume":"28","author":"HY Zou","year":"2015","unstructured":"Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, et al. PF-06463922, an ALK\/ROS1 Inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70\u201381.","journal-title":"Cancer Cell"},{"issue":"2","key":"9269_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"2","key":"9269_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1017\/S0016672399004462","volume":"75","author":"JC Whittaker","year":"2000","unstructured":"Whittaker JC, Thompson R, Denham MC. Marker-assisted selection using ridge regression. Genet Res. 2000;75(2):249\u201352.","journal-title":"Genet Res"},{"key":"9269_CR14","doi-asserted-by":"crossref","unstructured":"Chen T, Guestrin, C. Xgboost: A scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining; 2016, pp. 785\u2013794.","DOI":"10.1145\/2939672.2939785"},{"issue":"1","key":"9269_CR15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression shrinkage and selection via the lasso. J Roy Stat Soc: Ser B (Methodol). 1996;58(1):267\u201388.","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"issue":"1","key":"9269_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/00401706.1970.10488634","volume":"12","author":"AE Hoerl","year":"1970","unstructured":"Hoerl AE, Kennard RW. Ridge regression: biased estimation for nonorthogonal problems. Technometrics. 1970;12(1):55\u201367.","journal-title":"Technometrics"},{"key":"9269_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1467-9868.2005.00503.x","volume":"67","author":"H Zou","year":"2003","unstructured":"Zou H, Hastie T. Regression shrinkage and selection via the elastic net, with applications to microarrays. JR Stat Soc Ser B. 2003;67:301\u201320.","journal-title":"JR Stat Soc Ser B"},{"issue":"4","key":"9269_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1037\/0097-7403.27.4.354","volume":"27","author":"CR Gallistel","year":"2001","unstructured":"Gallistel CR, Mark TA, King AP, Latham PE. The rat approximates an ideal detector of changes in rates of reward: implications for the law of effect. J Exp Psychol Anim Behav Process. 2001;27(4):354\u201372.","journal-title":"J Exp Psychol Anim Behav Process"},{"issue":"9","key":"9269_CR19","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1158\/1535-7163.MCT-19-0105","volume":"18","author":"M Couetoux du Tertre","year":"2019","unstructured":"Couetoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, et al. Analysis of the genomic landscape in ALK\u2009+\u2009NSCLC patients identifies novel aberrations associated with clinical outcomes. Mol Cancer Ther. 2019;18(9):1628\u201336.","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"9269_CR20","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377.","journal-title":"N Engl J Med"},{"issue":"207","key":"9269_CR21","doi-asserted-by":"publisher","first-page":"ra142","DOI":"10.1126\/scitranslmed.3007013","volume":"5","author":"XJ Li","year":"2013","unstructured":"Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, Lee LW, McLean M, Law S, Butler H, Schirm M, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med. 2013;5(207):ra142.","journal-title":"Sci Transl Med"},{"issue":"1","key":"9269_CR22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Methodol). 1995;57(1):289\u2013300.","journal-title":"J Roy Stat Soc Ser B (Methodol)"},{"issue":"43","key":"9269_CR23","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"9269_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.21037\/tlcr.2018.05.13","volume":"7","author":"SM Hanash","year":"2018","unstructured":"Hanash SM, Ostrin EJ, Fahrmann JF. Blood based biomarkers beyond genomics for lung cancer screening. Transl Lung Cancer Res. 2018;7(3):327\u201335.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"9269_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41419-017-0212-3","volume":"9","author":"CT Yang","year":"2018","unstructured":"Yang CT, Li JM, Chu WK, Chow SE. Downregulation of lumican accelerates lung cancer cell invasion through p120 catenin. Cell Death Dis. 2018;9(4):414.","journal-title":"Cell Death Dis"},{"issue":"Suppl 3","key":"9269_CR26","doi-asserted-by":"publisher","first-page":"S348","DOI":"10.1245\/s10434-012-2441-0","volume":"20","author":"M de Wit","year":"2013","unstructured":"de Wit M, Belt EJ, Delis-van Diemen PM, Carvalho B, Coupe VM, Stockmann HB, Bril H, Belien JA, Fijneman RJ, Meijer GA. Lumican and versican are associated with good outcome in stage II and III colon cancer. Ann Surg Oncol. 2013;20(Suppl 3):S348\u201359.","journal-title":"Ann Surg Oncol"},{"key":"9269_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pharmthera.2019.02.015","volume":"198","author":"N Enz","year":"2019","unstructured":"Enz N, Vliegen G, De Meester I, Jungraithmayr W. CD26\/DPP4\u2014a potential biomarker and target for cancer therapy. Pharmacol Ther. 2019;198:135\u201359.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"9269_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1155\/2012\/706745","volume":"32","author":"M Javidroozi","year":"2012","unstructured":"Javidroozi M, Zucker S, Chen WT. Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer. Dis Markers. 2012;32(5):309\u201320.","journal-title":"Dis Markers"},{"issue":"6","key":"9269_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5306\/wjco.v2.i6.245","volume":"2","author":"OJ Cordero","year":"2011","unstructured":"Cordero OJ, Imbernon M, Chiara LD, Martinez-Zorzano VS, Ayude D, de la Cadena MP, Rodriguez-Berrocal FJ. Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol. 2011;2(6):245\u201361.","journal-title":"World J Clin Oncol"},{"issue":"4","key":"9269_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1074\/mcp.M114.045914","volume":"14","author":"PJ Liu","year":"2015","unstructured":"Liu PJ, Chen CD, Wang CL, Wu YC, Hsu CW, Lee CW, Huang LH, Yu JS, Chang YS, Wu CC, et al. In-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery. Mol Cell Proteomics. 2015;14(4):917\u201332.","journal-title":"Mol Cell Proteomics"},{"issue":"11","key":"9269_CR31","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1074\/mcp.M114.038836","volume":"13","author":"A Nazarian","year":"2014","unstructured":"Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, Villanueva J, Saghatelian A, Assel M, Vickers AJ, et al. Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Mol Cell Proteomics. 2014;13(11):3082\u201396.","journal-title":"Mol Cell Proteomics"},{"issue":"8","key":"9269_CR32","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","volume":"18","author":"JM Llovet","year":"2012","unstructured":"Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, Group SIS. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(8):2290\u2013300.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-020-9269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-020-9269-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-020-9269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T05:07:52Z","timestamp":1722402472000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalproteomicsjournal.biomedcentral.com\/articles\/10.1186\/s12014-020-9269-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9269"],"URL":"https:\/\/doi.org\/10.1186\/s12014-020-9269-6","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"type":"print","value":"1542-6416"},{"type":"electronic","value":"1559-0275"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"13 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board at each participating hospital and complied with Good Clinical Practices, the principles of the Declaration of Helsinki and all applicable regulatory requirements. All patients provided written informed consent prior to any study specific procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I\u2009=\u2009Immediate Family Member, Inst\u2009=\u2009My Institution. Relationships may not relate to the subject matter of this manuscript. Mathilde Cou\u00ebtoux du Tertre, Maud Marques, Lise Tremblay No relationship to disclose. Nicole Bouchard Consulting\/Advisory role for Pfizer, Astra Zeneca, Merck, BMS. Honoraria: Astra Zeneca, Merck, BMS. Research funding: Pfizer, BMS. Razvan Diaconescu, Vincent Pelsser, Valerie Higenell, Luisa Izzi, Karen Gambaro, Cyrla Hoffert, Gwena\u00ebl Pottiez, Alan Spatz, Suzan McNamara, Victor Cohen: No relationship to disclose. Normand Blais: Consulting\/Advisory role for Pfizer, Astra Zeneca, Merck, BMS, Sanofi, Roche, Boehringer Ingelheim, Bayer. Research funding: Merck. Christian Couture: Consulting\/Advisory role for Pfizer, BMS, Roche, Astra Zeneca, Merck, Abbvie. Research funding: Pfizer, Merck. Hangjun Wang: Consulting\/Advisory role for Merck, Pfizer, Astra Zeneca. Laura McIntosh, Val\u00e9rie Hindie, St\u00e9phane Parent, Laetitia Cortes, Pascal Croteau, Yannick-Andr\u00e9 Breton: Caprion Biosciences Inc. employee at the time the work was performed. Gerald Batist: Works with multiple pharma, including Pfizer, Roche, BMS, Novartis and others on clinical trials unrelated to this present work. Jason Agulnik: Consulting\/Advisory role for Takeda, Roche, Boehringer Ingelheim, Novartis. Honoraria: Astra Zeneca, BMS, Merck, Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}